NTT/MLB
NTT (TOKYO:9432), a global technology and business solutions leader, and Major League Baseball (MLB) today successfully conducted a Proof of Concept (PoC) with NTT’s Ultra Reality Viewing technology (URV) as part of their recently announced multi-year technology agreement making the Japan-based company an official MLB partner in the United States. This implementation verified the feasibility of a real-time super-high definition surround video fan experience event, a first for a live sporting event in the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191007005873/en/
A key foundation of the partnership is a collaborative intent to create a new fan experience in the Smart World era. Ultra Reality Viewing was successfully proven at Game 3 of the American League Division Series presented by Doosan between the Houston Astros and Tampa Bay Rays from Tropicana Field. In the ballpark, NTT installed multiple 4K cameras that transmitted high definition images (12K wide) in real time to a super-wide screen (90.6 in x 469 in) with 6ch surround sound including original audio sauce to a viewing area set up at MLB Network’s studio in Secaucus, NJ. This URV technology created a uniquely transformative sensation that put the remote viewer into the ballpark and its atmosphere live.
Enterprise Partners were invited to this viewing event in order to increase the awareness for other potential uses of this Ultra Reality Viewing experience technology. NTT and MLB will continue to work toward expanding the use of URV Technology for new and exciting fan experiences in other events.
URV Movie: https://youtu.be/De3UsAF0Ebc
Notes:
About Ultra Reality Viewing
Ultra Reality Viewing is NTT’s real-time super high-definition surround video synthesis technology that combines multiple 4K camera images into a super-wide image such as 12K in real-time and transmits them synchronously to remote locations. With the super high-definition surround videos which cannot be captured by general cameras and audio technologies which enable original sounds to generate and transmit to remote location without loss and time difference and regenerate those certain sounds fields through the remote location, audiences can view sports or events content as if they were watching it live in the stadium, on the field or in the theatre. This is a proven solution based on NTT’s unique R&D technology, “Kirari!(*1).” It has been successfully implemented in Japan to enhance audience viewing and fan experiences with very positive results.
(*1) For more information about NTT R&D technology “Kirari!”, please visit https://www.ntt.co.jp/activity/en/innovation/kirari/ .
About MLB
Major League Baseball (MLB) is the most historic professional sports league in the United States and consists of 30 member clubs in the U.S. and Canada, representing the highest level of professional baseball. Major League Baseball is the best-attended sport in North America, and since 2004, MLB has enjoyed its best-attended seasons in the history of the game. Led by Commissioner Robert D. Manfred, Jr., MLB currently features record levels of labor peace, competitive balance and industry revenues, as well as the most comprehensive drug-testing program in American professional sports. MLB remains committed to making an impact in the communities of the U.S., Canada and throughout the world, perpetuating the sport’s larger role in society and permeating every facet of baseball’s business, marketing and community relations endeavors. With the continued success of MLB Network and MLB digital platforms, MLB continues to find innovative ways for its fans to enjoy America’s National Pastime and a truly global game. For more information on Major League Baseball, visit www.MLB.com .
About NTT
NTT is a global technology and business solutions provider. We help clients grow their business and improve their competitive market position by delivering fully integrated services, including global networks, cybersecurity, managed IT and applications, cloud and datacenter services combined with business consulting and deep industry expertise. As a top-five global technology and business services provider, NTT works with over 80 of the Global Fortune 100 companies and many thousands of other clients and communities to achieve their goals and contribute to a sustainable future. For more information on NTT, visit www.global.ntt .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005873/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release
MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom